5C: Immune Engineering (SIG) 1

Timeslot: Thursday, April 20, 2023 - 3:45pm to 5:45pm
Room: Silver Pearl 3

About

Over the past decade the focus of many bioengineers and clinicians has been shifting towards "immune engineering" approaches that include but are not limited to engineered biomaterials for vaccines, immunotherapy (immune-modulation), cell and gene therapy, immune microenvironment engineering, and systems immunology. These research areas embrace a comprehensive list of translational immunology-associated problems including chronic infections, autoimmune diseases, aggressive cancers, allergies, etc. The purpose of the Immune Engineering SIG is to bring together emerging ideas and provide a venue for professional interaction to a large number of academic and industrial research groups and scientists working in these areas.

  • 3:45 PM 217. Transient Injectable Stimulatory Hydrogels to Improve the Efficacy of CAR-T Therapies of Solid Tumors. Eric Appel, PhD, Stanford University, Stanford, CA, USA.

  • 4:00 PM 218. Lipid Nanoparticle Composition Shapes Immune Response to mRNA Vaccine and Potency of Anticancer Immunity. Yining Zhu, Jingyao Ma, Ruochen Shen, Ivan Vuong, Hai-Quan Mao, Johns Hopkins University, Baltimore, MD, USA.

  • 4:15 PM 219. Non-Inflammatory mRNA Vaccine for Antigen-Specific Immunomodulation in the Lung. Atanu Chakraborty, PhD, Shruti Dharmaraj, MS, Nhu Truong, Ryan Pearson, PhD, University of Maryland, Baltimore, Baltimore, MD, USA.

  • 4:30 PM 220. Biomaterial-based Ex vivo Natural Killer Cell Surface Engineering for Enhanced Cancer Immunotherapy. Sungjun Kim, PhD Student, Kyobum Kim, PhD, Dongguk University, Seoul, Republic of Korea.

  • 4:45 PM 221. PEGylation of Indoleamine 2,3-Dioxygenase for Systemic Immune Regulation. "Jennifer Simonovich, Alexander Kwiatkowski, Arun Wanchoo, Dorina Avram, Benjamin Keselowsky, University of Florida, Gainesville, FL, USA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

  • 5:00 PM 222. Human Stem Cell Derived Beta-Like Cells Engineered to Present PD-L1 Improve Transplant Survival in NOD Mice Carrying Human HLA Class I. Jorge Santini-Gonzalez, Roberto Castro-Gutierrez, Matthew Becker, Chad Rancourt, Holger Russ, PhD, Edward Phelps, PhD, University of Florida, Gainesville, FL, USA, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

  • 5:15 PM 223. Vaccines Restore Homeostasis in Collagen Induced Arthritis Mice. Abhirami Thumsi, Srivatsan Swaminathan, Abhirami Suresh, Arezoo Esrafili, Madhan Jaggarapu, Kelly Lintecum, Michelle Halim, Tyler Johnston, Yasmin Sleiman, Shivani Mantri, Abhinav Acharya, Arizona State University, Tempe, AZ, USA.

  • 5:30 PM 224. Tissue-Engineered Stromal Reticula to Study Tolerogenic Fibroblastic Reticular Cell Properties in Type 1 Diabetes. Leonor Teles, Zachary Wilkes, Remi Creusot, Alice Tomei, Diabetes Research Institute, Miami, FL, USA, University of Miami, Coral Gables, FL, USA, Columbia Center for Translational Immunology, New York, NY, USA, Naomi Berrie Diabetes Center, New York, NY, USA.